NCT00258115已完成2 期
The Study of Inhibition of Inflammation in the Dysmetabolic Syndrome of Obesity
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- glycemia
研究概览
简要总结
Chronic subaccute inflammation may underlie the development of diabetes cardiovascular disease and other components of the metabolic syndrome. Rodent studies suggest diet induced obesity is associated with activation of the IKK/NF-kB pathway and this pathway can be inhibited by salicylates. This study seeks to determine the effect of salicylates in overweight persons.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 30 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •obesity (> 85th% for age,BMI > 30); HbA1c <6%; hemoglobin and/or hematocrit within 2 standard deviations of normal range, without high risk of bleeding, without donation of blood in the previous 2 months; without involvement in any study evaluating an investigational drug or device for the previous 2 months; normal clotting studies; if female using barrier or oral contraception and with a negative pregnancy test.
排除标准
- •Pregnant or lactating women; Patients with abnormal liver function defined as elevation of bilirubin, alkaline phosphatase, ALT, AST, or GGTP more than 1.5 times the upper limit of normal; Patients with kidney disease (serum creatinine > 1.5 mg/dL) macroalbuminuria (1+ protein on a standard urine dip-stick, or > 300 mg urinary albumin/day); (patients with microalbuminuria will be enrolled); Patients with any significant diseases or conditions, including emotional or psychiatric disorders and substance abuse, including history of binge drinking, that, in the opinion of the investigator, are likely to alter the patient's ability to complete the study ; Patients with metabolic acidosis (abnormal anion gap); History of gastric ulcer, dyspepsia, or upper or lower GI bleed; History of allergy to aspirin, or bleeding diathesis or currently on oral anticoagulants including warfarin, heparin, aspirin or other NSAIDs; Patients with major vascular event within 6 months of screening for the study (e.g., MI, stroke, CABG, angioplasty, PV surgery); Patients with chronic heart disease, or a history of myocardial infarction or stroke. Symptomatic angina pectoris or cardiac insufficiency as defined by the NYHA; classification as Functional Class III or IV; Patients who smoke more than one pack of cigarettes daily; Patients taking treatment medications known to affect insulin sensitivity (e.g. diuretics, beta-blockers); Patients with inadequately controlled serum lipid levels (total cholesterol ≥ 275 mg/dL and fasting triglycerides ≥ 450 mg/dL); Patients with history of cancer within 5 years prior to screening for the study other than basal cell carcinoma; active alcohol or other substance abuse.
研究组 & 干预措施
salsalate
Active Comparator
4.0 g/d divided dosing
干预措施: salsalate (Drug)
placebo
Placebo Comparator
placebo for salsalate
干预措施: salsalate (Drug)
结局指标
主要结局
glycemia
时间窗: one month
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
1 期
The effect of inflammatory mechanism on diabetic limb arterial occlusion and the intervention of ruanjiantongmai granuleITMCTR2000003290Shanghai TCM-Integrated Hospita
招募中
不适用
Association of Inflammatory Factors With Complications in the Diabetic Population: a Cross-sectional StudyDiabetes MellitusNCT06651983Nanfang Hospital, Southern Medical University3,000
已完成
不适用
Changes in Hematological Parameters With Glycemia Control in Type 2 DiabetesPoorly Controlled Diabetes MellitusNCT06228898Goztepe Prof Dr Suleyman Yalcın City Hospital170
终止
2 期
Inflammation Inhibition in Prediabetic HumansObesePrediabetesNCT01977417Gary L. Pierce21
已完成
4 期
Rapid Effects Linagliptin on Monocyte Polarization and Endothelial Progenitor Cells in Type 2 DiabetesType 2 DiabetesChronic Renal FailureNCT01617824University of Padova45